• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by DENTSPLY SIRONA Inc.

    7/1/25 4:21:57 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    S-8 1 ds-formsx806262025.htm S-8 Document

    As filed with the Securities and Exchange Commission on July 1, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933


    DENTSPLY SIRONA Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    39-1434669
    (I.R.S. Employer
    Identification No.)

    13320 Ballantyne Corporate Place
    Charlotte, North Carolina 28277-3607
    (Address of principal executive offices)

    DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (as amended on May 21, 2025)
    (Full title of the plan)

    Richard C. Rosenzweig
    Executive Vice President, Corporate Development, General Counsel and Secretary
    DENTSPLY SIRONA Inc.
    13320 Ballantyne Corporate Place
    Charlotte, North Carolina 28277-3607
    (844) 848 - 0137
    (Name, address and telephone number,
    including area code, of agent for service)

    With copies to:
    Lillian Tsu & Julia L. Petty
    Cleary Gottlieb Steen & Hamilton LLP
    One Liberty Plaza
    New York, New York 10006

    ________________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
    Large accelerated filer    ☒    Accelerated filer    ☐
    Non‑accelerated filer    ☐  (Do not check if a smaller reporting company)    Smaller reporting company    ☐
    Emerging growth company    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐




    EXPLANATORY NOTE
    Pursuant to General Instruction E of Form S-8, DENTSPLY SIRONA Inc. (the “Registrant”) is filing this registration statement on Form S-8 (this “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register, in connection with the Registrant’s 2024 Omnibus Incentive Plan (as amended on May 21, 2025), an additional 11,260,000 shares of the same class as registered under the Registrant’s effective registration statement on Form S-8, File No. 333-279714, filed with the Commission on May 24, 2024 (the “Earlier Registration Statement”). The contents of the Earlier Registration Statement, where applicable, are hereby incorporated by reference, except that the provisions contained in Part II of such Earlier Registration Statement are modified as set forth in this Registration Statement.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.Incorporation of Documents by Reference.
    The following documents, as filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference in this Registration Statement:
    (1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;
    (2)The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Commission on May 8, 2025;
    (3)The Registrant’s Current Reports on Form 8-K filed with the Commission on February 6, 2025 (excluding Item 7.01 and Exhibit 99.1), March 19, 2025, May 8, 2025 (excluding Item 2.02 and Exhibit 99.1), May 22, 2025, May 29, 2025 (excluding Item 7.01, Exhibit 10.1, and Exhibit 99.1), June 4, 2025, June 6, 2025, and June 12, 2025; and
    (4)The description of the Registrant’s Common Stock, par value $0.01 per share, contained in Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 2, 2020, including any amendment or report filed for the purpose of updating such description.
    In addition, all reports and other documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post‑effective amendment to this Registration Statement that indicates that all securities offered hereunder have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any document or any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.







    Item 8.    Exhibits.
    Exhibit
    Number
    Description
    4.1
    Second Amended and Restated Certificate of Incorporation of DENTSPLY International Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Commission on March 1, 2017)
    4.2
    Certificate of Amendment to Second Amended and Restated Certificate of Incorporation of DENTSPLY SIRONA Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on May 23, 2018)
    4.3
    Seventh Amended and Restated By-Laws of DENTSPLY SIRONA Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on August 2, 2023)
    4.4
    DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 filed with the Commission on May 24, 2024)
    4.5
    Amendment No. 1 to the DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Appendix A of the Registrant’s 2025 Proxy Statement filed with the Commission on April 9, 2025)
    5.1
    Opinion of Cleary Gottlieb Steen & Hamilton LLP
    23.1
    Consent of Cleary Gottlieb Steen & Hamilton LLP (included in Exhibit 5.1)
    23.2
    Consent of Independent Registered Public Accounting Firm - Deloitte & Touche LLP
    23.3
    Consent of Independent Registered Public Accounting Firm - PricewaterhouseCoopers LLP
    24.1
    Power of Attorney (contained on signature page hereto)
    107
    Filing Fee Table




    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Charlotte, North Carolina on the 1st day of July, 2025.
    DENTSPLY SIRONA INC.
    Date: July 1, 2025By:/s/ Simon D. Campion
    Simon D. Campion
    President and Chief Executive Officer
    POWER OF ATTORNEY

    Each person whose signature appears below appoints Simon D. Campion and Richard C. Rosenzweig, each of whom may act without joinder of the other, the individual’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments (including post-effective amendments) to this Registration Statement and any registration statement for the same offering, filed pursuant to Rule 462 under the Securities Act, and to file the same with all exhibits thereto and all documents in connection therewith with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully and for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or their substitutes may lawfully do or cause to be done by virtue hereof.




    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    NameTitleDate
    /s/ Simon D. CampionPresident and Chief Executive Officer and DirectorJuly 1, 2025
    Simon D. Campion(Principal Executive Officer)
    /s/ Matthew E. Garth
    Executive Vice President and Chief Financial Officer July 1, 2025
    Matthew E. Garth(Principal Financial Officer)
    /s/ Kevin J. Czerney
    Chief Accounting OfficerJuly 1, 2025
    Kevin J. Czerney(Principal Accounting Officer)
    /s/ Gregory T. Lucier
    Chairman of the Board of DirectorsJuly 1, 2025
    Gregory T. Lucier
    /s/ Michael J. BarberDirectorJuly 1, 2025
    Michael J. Barber
    /s/ Willie A. DeeseDirectorJuly 1, 2025
    Willie A. Deese
    /s/ Brian T. GladdenDirectorJuly 1, 2025
    Brian T. Gladden
    /s/ Betsy D. HoldenDirectorJuly 1, 2025
    Betsy D. Holden
    /s/ Clyde R. HoseinDirectorJuly 1, 2025
    Clyde R. Hosein
    /s/ Jonathan J. MazelskyDirectorJuly 1, 2025
    Jonathan J. Mazelsky
    /s/ Daniel T. ScavillaDirectorJuly 1, 2025
    Daniel T. Scavilla
    /s/ Leslie F. VaronDirectorJuly 1, 2025
    Leslie F. Varon
    /s/ Janet S. VergisDirectorJuly 1, 2025
    Janet S. Vergis


    Get the next $XRAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    12/9/2025$12.00Underweight
    Barclays
    11/7/2025Outperform → Mkt Perform
    William Blair
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    More analyst ratings

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26

    CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http

    2/5/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Wellspect HealthCare Launches Surity™ Female External Catheter Improving Care for Women Living with Severe Urinary Incontinence

    MÖLNDAL, Sweden, Jan. 26, 2026 /PRNewswire/ -- Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative Surity™ Female External Catheter, a new non-invasive solution designed to support women living with severe urinary incontinence. Wellspect HealthCare has been a trusted healthcare leader and at the forefront of innovation for more than 40 years, with established product brands including LoFric® and Navina™. Surity™ marks Wellspect's entry into a new category, bringing people suffering from severe urinary incontinence, and their caregivers, a reliable and comfortable urinary incontinence management solution.

    1/26/26 8:15:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Patterson Dental and Dentsply Sirona Renew U.S. Dental Technology Distribution Partnership

    CHARLOTTE, N.C., Jan. 14, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, and Patterson Dental Holdings ("Patterson Dental"), a leading supplier of products and services to the dental and animal health end markets, today announced the renewal of their U.S. dental technology distribution agreement. This renewed partnership reflects both companies' commitment to supporting dental professionals with advanced technologies and expert service while setting a clear focus on driving growth and innovation in the years ahead. A Partnership Focused on the Future Dentsply S

    1/14/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zurbay Donald was granted 6,871 shares (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/27/26 5:02:46 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Zurbay Donald

    3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/15/26 4:23:39 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Vergis Janet S. was granted 201 shares, increasing direct ownership by 0.45% to 44,501 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/13/26 4:39:32 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    SEC Filings

    View All

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    1/14/26 7:55:51 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    1/13/26 7:55:17 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    12/31/25 4:25:54 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Varon Leslie F bought $99,999 worth of shares (9,337 units at $10.71), increasing direct ownership by 19% to 57,343 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    11/25/25 5:26:33 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/25 6:33:03 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

    4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/29/25 6:14:01 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Dentsply Sirona with a new price target

    Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00

    12/9/25 8:44:01 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona downgraded by William Blair

    William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform

    11/7/25 8:28:06 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

    4/15/25 9:24:19 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization

    CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company's focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successf

    10/2/25 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/12/24 4:23:31 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26

    CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http

    2/5/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Declares Quarterly Cash Dividend

    CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den

    12/15/25 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports Third Quarter 2025 Results

    Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation strategy CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its f

    11/6/25 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care